Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride

NCT02580305 is registered in ClinicalTrials.gov with Suven Life Sciences Limited as lead sponsor.

NCT NCT02580305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02580305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Lead sponsor
Suven Life Sciences Limited
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2015
Completion date
November 7, 2019
Enrollment
564 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease